DEF: BiomX Seeks Reverse Stock Split, Elects Directors

BiomX Inc. will hold its 2025 Annual Meeting to elect directors, ratify auditors, and seek authorization for a reverse stock split to boost share price and facilitate capital raising.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on Thursday, October 16, 2025, at 8:00 a.m. Eastern Time.
• Stockholders will vote on the election of three Class II directors to serve until the 2028 annual meeting.
• A key proposal seeks authorization for the Board to amend the certificate of incorporation to effect a reverse stock split of common stock at any ratio between 1-for-5 and less than 1-for-20, at the Board's discretion, before October 16, 2026.
• The purpose of the proposed reverse stock split is to attract institutional investors with minimum trading price requirements and assist in capital-raising efforts.
• Stockholders will also vote to ratify the appointment of Kesselman & Kesselman (PricewaterhouseCoopers International Limited) as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board recommends voting FOR all proposals, including the election of directors, the reverse stock split authorization, the auditor ratification, and the approval to adjourn the meeting if necessary to solicit additional votes.
• As of the record date, August 22, 2025, 26,554,887 shares of common stock were outstanding and entitled to vote.

Sentiment

Score: 3

Explanation: The company's financial performance, marked by declining net income and a severely negative Total Shareholder Return over the past three years, indicates significant challenges. While recent capital raises provide some liquidity, the necessity of a reverse stock split to improve market perception and facilitate future funding suggests underlying stock price weakness and a difficult operating environment. The overall financial trajectory and the need for such a measure point to a high-risk investment profile.

Positives

• The Board is seeking flexibility for a reverse stock split, which could potentially attract a broader range of institutional investors and facilitate future capital raising efforts.
• The company has a structured corporate governance framework with a majority of independent directors (7 out of 8) and established committees (Audit, Compensation, Nominating & Corporate Governance).
• The company successfully completed a private placement transaction (March 2024 PIPE) raising approximately $50 million in gross proceeds.
• A subsequent financing round in February 2025 also secured additional capital from key investors including Deerfield, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, and AIGH.

Negatives

• Net income has declined year-over-year, from $28,317 thousand in 2022 to $26,169 thousand in 2023, and further to $17,727 thousand in 2024.
• Total Shareholder Return (TSR) has significantly eroded, with an initial $100 investment declining to $17.50 in 2022, $11.69 in 2023, and $4.56 in 2024.
• The need for a reverse stock split indicates a low current stock price, which may be below thresholds for institutional investors or desirable for exchange listing maintenance.
• Executive compensation, specifically 'Compensation Actually Paid,' decreased for the PEO and Non-PEO NEOs from 2023 to 2024.
• Several directors and executive officers, along with OrbiMed Israel Partners Limited Partnership, had delinquent Section 16(a) reports filed with the SEC.

Risks

• The market price of common stock may decline after a reverse stock split, despite the intention to increase it, due to factors outside the company's control.
• A reverse stock split could adversely affect the liquidity of common stock, especially for larger block trades.
• Stockholders may own 'odd-lots' (less than 100 shares) after a reverse stock split, which generally incur higher brokerage commissions and transaction costs.
• The reverse stock split could have an anti-takeover effect by increasing authorized but unissued shares, potentially diluting ownership or voting rights of persons seeking control.
• Dilution of ownership interest for current holders if additional shares are issued from the increased pool of authorized but unissued shares after the reverse stock split.
• There is no assurance that any future transactions, such as equity offerings or mergers, will be consummated on favorable terms or enhance stockholder value.
• The U.S. federal income tax consequences of the reverse stock split are based on existing law and may be subject to change, with no assurance that the discussed tax consequences would be accepted by the IRS or a court.

Future Outlook

The Board may implement a reverse stock split at its discretion before October 16, 2026, if approved by stockholders, to increase the trading price of common stock, attract institutional investors, and assist in capital-raising efforts. The company expects to continue filing periodic and current reports and maintain its NYSE American listing under the symbol PHGE. The Board retains the authority not to effect the reverse stock split even if approved.

Management Comments

• Jonathan Solomon (CEO): "Your vote is very important! Whether or not you plan to attend the Annual Meeting, we urge you to read the enclosed proxy statement and vote as soon as possible."
• Board of Directors: "The Board unanimously recommends that you vote FOR each of the Class II director nominees in Proposal No. 1."
• Board of Directors: "The Board unanimously recommends that you vote FOR the authorization of our Board to amend the Certificate of Incorporation to effect a reverse stock split..."
• Board of Directors: "The Board believes that by having separate roles, the Chief Executive Officer is able to focus on the day-to-day business and affairs of the Company and the Chairman is able to focus on key strategic issues, board leadership and communication."
• Board of Directors: "We are submitting this proposal to our stockholders for approval to help attract institutional investors with minimum trading price requirements. We believe increasing the trading price of our Common Stock will also assist in our capital-raising efforts by making our Common Stock more attractive to a broader range of investors."

Industry Context

The company operates in the biotechnology and pharmaceutical industry, as evidenced by the backgrounds of its executive officers and directors who have experience in drug research, clinical development, infectious diseases, oncology, and diabetes mellitus. The proposed reverse stock split is a common strategy for companies in capital-intensive sectors, particularly those with lower stock prices, to meet exchange listing requirements or attract institutional investment. The recent private placements and financing rounds highlight the ongoing need for capital in the biotech industry for research, development, and commercialization.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry benchmarking.
• Aon Solutions UK Limited was retained as an independent compensation consultant to provide competitive market data for executive officers, suggesting an effort to align compensation with industry standards, though specific benchmarks are not disclosed.

Management Changes

Corporate Governance

Related Party Transactions

• On March 6, 2024, the company entered into a Securities Purchase Agreement with certain investors, including the Cystic Fibrosis Foundation (CFF), OrbiMed Israel GP Ltd. (Orbimed), and Telmina Limited (Telmina), each holding more than 5% of outstanding common stock. This private placement involved the sale of 216,417 shares of Convertible Preferred Stock and warrants to purchase up to 108,208,500 shares of common stock for approximately $50 million in gross proceeds. CFF purchased $5 million, Orbimed $1 million, and Telmina $0.6 million of these securities.
• In February 2025, the company completed a financing round (February 2025 Financing) with certain investors, including Deerfield Management Company, L.P. (Deerfield), CFF, and Nantahala Capital Management, LLC (Nantahala), each holding more than 5% of outstanding common stock. This financing involved the issuance of unregistered warrants (New Warrants) and other securities. CFF contributed $2.1 million, Deerfield $3 million, Nantahala $1.2 million, and AIGH approximately $0.7 million.

Stakeholder Impact

• **Shareholders**: Will vote on critical proposals, including director elections and a reverse stock split. Face potential benefits from a higher stock price and increased investor interest if the reverse split is successful, but also risks of further price decline, reduced liquidity, and potential anti-takeover effects. Have experienced significant decline in Total Shareholder Return over the past three years.
• **Employees**: Executive officers' compensation includes salary, bonus, stock awards, and option awards. A successful reverse stock split could potentially aid in attracting and retaining talent by improving stock perception.
• **Investors (Institutional)**: The proposed reverse stock split is specifically aimed at attracting institutional investors who may have minimum trading price requirements, potentially broadening the investor base.

Next Steps

• Stockholders are urged to vote on the proposals for the Annual Meeting by October 16, 2025.
• If approved, the Board may, at its sole discretion, effect a reverse stock split at any time before October 16, 2026.
• The company expects to file a Current Report on Form 8-K with the SEC within four business days after the Annual Meeting to publish final voting results.
• Stockholder proposals for inclusion in the 2026 annual meeting proxy statement must be received by April 30, 2026.
• Notices for director nominees to be included on the proxy card for the 2026 annual meeting under Rule 14a-19 must be received by August 17, 2026.

Key Dates

Recommendation

The company's financial performance, characterized by declining net income and a drastic reduction in Total Shareholder Return over the last three fiscal years, indicates significant operational and market challenges. The proposal for a reverse stock split, while intended to improve market perception and facilitate capital raises, is often a reactive measure to a low stock price and carries inherent risks such as further price decline and reduced liquidity. Although recent capital raises provide some financial runway, the underlying negative trends and the need for such a measure suggest a high-risk investment profile with limited near-term upside potential. A seasoned investor would likely view these factors as strong indicators of continued underperformance and advise divesting.

Keywords

BiomX Inc., PHGE, Proxy Statement, Annual Meeting, Reverse Stock Split, Director Election, Corporate Governance, Capital Raise, Financial Performance, Biotechnology, SEC Filing, Shareholder Vote, Risk Oversight, Executive Compensation